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The aim of the study was to investigate the associations between UGT1A1*28 genotype and (1) response rates, (2) febrile
neutropenia and (3) dose intensity in patients with metastatic colorectal cancer treated with irinotecan. UGT1A1*28 genotype was
determined in 218 patients receiving irinotecan (either first-line therapy with capecitabine or second-line as monotherapy) for
metastatic colorectal cancer. TA7 homozygotes receiving irinotecan combination therapy had a higher incidence of febrile
neutropenia (18.2%) compared to the other genotypes (TA6/TA6:1.5%; TA6/TA7:6.5%, P¼0.031). TA7 heterozygotes receiving
irinotecan monotherapy also suffered more febrile neutropenia (19.4%) compared to TA6/TA6 genotype (2.2%; P¼0.015).
Response rates among genotypes were not different for both regimens: combination regimen, P¼0.537; single-agent, P¼0.595. TA7
homozygotes did not receive a lower median irinotecan dose, number of cycles (P-values X0.25) or more frequent dose reductions
compared to the other genotypes (P-values for trend; combination therapy: 0.62 and single-agent: 0.45). Reductions were mainly
(480%) owing to grade X3 diarrhoea, not (febrile) neutropenia. TA7/TA7 patients have a higher incidence of febrile neutropenia
upon irinotecan treatment, but were able to receive similar dose and number of cycles compared to other genotypes. Response rates
were not significantly different.
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Colorectal carcinoma is one of the most common cancers in the
western world and the second largest cause of cancer-related death
(Boyle and Ferlay, 2005). Approximately 50% of patients present
with distant metastases either at diagnosis or during follow-up for
which curative treatment is no longer possible. In the palliative
setting, the median overall survival has increased from approxi-
mately 8 months without treatment to approximately 21 months
using 5-fluorouracil (or its oral prodrug capecitabine), irinotecan
(IRI), oxaliplatin and targeted agents (Punt, 2004). One of the most
studied metabolic enzymes of the IRI pathway is uridine diphos-
phate glucuronosyl transferase, UGT1A1. It converts the active
metabolite of IRI, SN38, to its inactive glucuronide (Iyer et al,1 9 9 8 )
and is expressed in the liver, the relative amount being dependent
on the number of TA-repeats in the promoter of the gene (wild-type,
TA6 or UGT1A1*28, TA7). The TA7 allele results in lower UGT1A1
expression and decreased SN-38 glucuronidation (Ando et al, 1998,
2002; Iyer et al, 1999; Paoluzzi et al, 2004). TA7/TA7 patients,
therefore, have a higher SN38 exposure and hence an increased
chance to experience toxic side effects (Iyer et al, 2002; Innocenti
et al, 2004; Marcuello et al, 2004). One can also hypothesise that TA6
homozygotes may tolerate a higher IRI dosage, possibly increasing
treatment benefit. Indeed, several reports show that IRI dose can be
increased in a subset of patients (Merrouche et al, 1997; Ducreux
et al, 1999; Ychou et al, 2002), and there is indirect evidence that
the efficacy of IRI seems dose-dependent (Abigerges et al, 1995).
Recently, the FDA has approved the updated Camptosar
s (IRI)
product labelling that recommends a reduced starting dose for
TA7/TA7 patients to prevent haematological toxicity.
Our primary aim was to investigate the efficacy by genotype.
Secondly, we investigated the association between UGT1A1*28 and
febrile neutropenia as this concerns a clinically relevant complication
of treatment with IRI. It leads to hospital admissions and may pose a
serious medical problem, especially when occurring with diarrhoea.
Thirdly, we studied the number of IRI cycles and dosage by genotype.
PATIENTS AND METHODS
Subjects
Blood samples were obtained from patients enrolled in a multi-
centre phase III trial of the Dutch Colorectal Cancer Group
(DCCG), referred to as the CAIRO study. Eligibility criteria,
interim safety results (Koopman et al, 2006) and survival data Revised 9 May 2008; accepted 12 May 2008; published online 1 July 2008
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s(Koopman et al, 2007) have been published. Briefly, patients were
allocated to regimen A or B. Regimen A consisted of first-line
capecitabine (1250mgm
 2day
 1 b.i.d. on days 1–14, every 3
weeks), second-line IRI (350mgm
 2day
 1 on day 1, every 3
weeks) and third-line capecitabine plus oxaliplatin. Regimen B
consisted of first-line capecitabine (1000mgm
 2day
 1 b.i.d. on
days 1–14, every 3 weeks) plus IRI (250mg
 2day
 1 on day 1,
every 3 weeks: capecitabine plus IRI (CAPIRI), followed by second-
line capecitabine plus oxaliplatin. Initial IRI dose of 80% in cycle 1
was recommended when: age 470 years, WHO performance status
2 and/or serum bilirubin 1.0–1.5  upper limit of normal (ULN).
If well tolerated, the dose was increased to 100% in subsequent
cycles. Irinotecan dose was reduced with 25% relative to the
previous cycle in case of any grade 3–4 toxicity with the exception
of nausea/vomiting when adequate prophylaxis was still available.
If these toxicities recurred despite dose reduction, the dose was
reduced to 50% and upon next recurrence the treatment was
discontinued. Diarrhoea was treated with loperamide (2mg every
2h, for a minimum of 12h and a maximum treatment duration of
48h). Prophylactic use of haematological growth factors and
loperamide was not permitted. Inclusion took place from January
2003 to December 2004, and EDTA blood samples for genotyping
were collected from October 2003 to March 2005 after a protocol
amendment. The objective was to perform genetic association
studies regarding antitumour response and toxicity. The
study protocol and the amendment were approved by the local
ethical committees. Patients were asked to participate in this side-
study at inclusion, and written informed consent was obtained
from all patients participating in the genetic association study
before blood collection. DNA was obtained from 268 patients
(regimen B: 141 subjects; regimen A: 127). Of the patients in
regimen A, 83 continued to receive second-line therapy with IRI
(Figure 1).
Clinical evaluation
Tumour evaluation was performed by means of CT or MRI every
three cycles according to RECIST (Therasse et al, 2000) criteria
and results were blinded with respect to genotype data. Toxicity
was graded according to NCI common toxicity criteria version 2.0
(Anonymous, 1998). We used febrile neutropenia and worst grade
of diarrhoea experienced during treatment with IRI. Overall
toxicity was defined as any grade 3 or 4 toxicity that occurred
during treatment. Neutrophil counts were not routinely per-
formed, but all patients were instructed to contact the hospital in
case of fever. If so, neutrophil counts were determined. Irinotecan
dose was calculated as the sum of all IRI doses (mg) and as the sum
of all doses, divided by body surface area (BSA), mgm
 2. Body
Did not receive full dose in first cycle
Excluded: 
    No genotype available    (N=595)
    UGT1A1 5/5, 5/6 or 5/7   (N=3)
CAIRO 1 randomised patients N=820 
UGT1A1 TA6 or TA7   N=222 CAPIRI  n=138 
TA6/TA6 65
TA6/TA7 62
TA7/TA7 11
IRI  n=84 
TA6/TA6 47
TA6/TA7 31
TA7/TA7 6
Not eligible for irinotecan
Did not receive irinotecan treatment
IRI  n=80
TA6/TA6 46
TA6/TA7 31
TA7/TA7 3
CAPIRI  n=138 
TA6/TA6 65
TA6/TA7 62
TA7/TA7 11
Analysis  
Age 1
Bilirubin 2
Age+bilirubin 1
Age+PS 1
PS 1
BSA 1
Analysis drug administration
CAPIRI   n=130
TA6/TA6 61
TA6/TA7 58
TA7/TA7 11
Bilirubin >1.5ULN n=3
First-line therapy ongoing n=1
IRI  n=83 
TA6/TA6 46
TA6/TA7 31
TA7/TA7 6
CAPIRI  n=138
TA6/TA6 65
TA6/TA7 62
TA7/TA7
IRI  n=73
TA6/TA6 41
TA6/TA7 29
TA7/TA7 3
Age
BSA 3
5
11
Figure 1 Flowchart of patients in current analysis. Abbreviations: BSA¼body surface area; CAPIRI¼irinotecan first-line combination therapy
(250mgm
 2 every 3 weeks, with capecitabine); IRI¼irinotecan (350mgm
 2 every 3 weeks) second-line single-agent therapy; PS¼performance status;
ULN¼upper limit of normal.
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ssurface area was calculated with the Mosteller formula, based on
height and weight (at current or previous cycle). The relative dose
intensity, RDI, is the dose in mgm
 2 received divided by the
protocol dose and expressed in percentage. The overall RDI is the
sum of RDIs divided by the number of cycles received. A dose
reduction is defined as a reduction of at least 10% compared to the
previous dose. Dose reductions were analysed in patients receiving
at least two doses of IRI. DNA isolation and genotyping methods
are published online in the Supplementary Data file.
Statistics
All eligible patients with UGT1A1 TA6/TA6,T A 6/TA7 and TA7/TA7
genotypes who received IRI were considered for toxicity analysis.
Patients were included in response analysis, if they were evaluable
for response. In dosage analysis, we studied only those patients
who received a full starting dose. Patients who received only one
cycle were considered as having no recorded dose reduction.
Kruskal–Wallis, w
2 and (exact) Cochrane–Armitage trend tests
were used to investigate the association of genotypes and patient
characteristics. Logistic regression, stratified by regimen, was
performed to investigate the association of UGT1A1 with the
probability of febrile neutropenia. We performed bivariate
analyses of UGT1A1*28 and a separate covariate (gender, age, site
of primary tumour, prior chemotherapy, thymydilate synthase
(TS) 6bp deletion (Mandola et al, 2004), TS number of active
repeats (Pullarkat et al, 2001) (as defined by Mandola (Mandola
et al, 2003)), P-glycoproteins ABCB1 C1236T and ABCG2 C421A
(Smith et al, 2006)) to explore a possible association of these
variables with an adverse event.
All analyses were performed with SAS version 9.1.3; in all
analyses, P-values o0.05 were considered statistically significant.
We did not adjust for multiple comparisons, and therefore, this
study needs to be regarded as exploratory only.
A retrospective power analysis reveals that with the given
sample sizes and a genotype distribution of 45, 45 and 10% (TA6/
TA6,T A 6/TA7 and TA7/TA7, respectively), a Cochrane–Armitage
trend test could have detected realistic differences in response
rates (regimen A response rates: 6, 16 and 33% (TA6/TA6;T A 6/TA7
and TA7/TA7, respectively) and regimen B: 34, 50 and 57%) with
P¼0.05 at b¼0.8.
RESULTS
UGT1A1 genotype frequencies were: 50.5% (n¼112) TA6 homo-
zygotes, 41.9% (n¼93) heterozygotes and 7.7% (n¼17) TA7
homozygotes. Other genotypes found were TA5/TA5 (n¼1),
TA5/TA6 (1) and TA5/TA7 (1); these uncommon genotypes were
excluded from the analysis. Patients were predominantly Cauca-
sian. Frequencies were in Hardy–Weinberg Equilibrium and in
accordance with the published results in Caucasians (Innocenti
et al, 2004; Paoluzzi et al, 2004; Carlini et al, 2005; Toffoli et al,
2006). Of patients receiving first-line CAPIRI, 127 patients were
evaluable for response and 138 for toxicity, and of the patients
receiving second-line IRI, these were 77 and 80, respectively.
Patient characteristics are shown in Table 1.
Tumour response
Overall objective tumour response (complete (CR) and partial (PR)
responses) in patients treated with CAPIRI was 47.2% (CRþPR)
and 14.3% for IRI. Patients with TA6/TA6 receiving CAPIRI
achieved 49.2% response, compared to 43.1% of TA6/TA7 and
62.5% of TA7/TA7 patients (P¼0.537; Table 2). Response rates for
IRI were: 15.9% TA6/TA6, and 13.3% TA6/TA7. Only stable diseases
were observed in TA7/TA7 patients receiving IRI.
Toxicity
Six of 138 patients receiving CAPIRI (5.1%) and in 7 of 80 patients
receiving IRI (8.8%) experienced neutropenic fever. The incidence
of febrile neutropenia in the CAPIRI regimen was 18.2% in TA7/
TA7 compared to 1.5% in TA6/TA6 and 6.5% in TA6/TA7 patients
(P¼0.031, Table 2). TA7 homozygotes receiving CAPIRI had
increased risk of 14.2 (OR 95% CI: 1.17–173) to develop
neutropenic fever compared to TA6 homozygotes. All TA7/TA7
patients developing febrile neutropenia experienced this adverse
effect in the first IRI cycle. Thirty-two of 138 patients receiving
CAPIRI (23.2%) and 16 of 80 patients receiving IRI (20.0%)
experienced severe diarrhoea (grade X3). Of the TA7 homozygotes
receiving CAPIRI, 36.4% experienced severe diarrhoea, as opposed
to 21.5% of TA6 homozygotes and 22.6% of heterozygotes (P-value
for trend: 0.43).
The incidence of febrile neutropenia was also higher
in TA7 heterozygotes receiving IRI (P¼0.015) relative to
TA6/TA6 patients. Of the TA6/TA6 patients treated with this
regimen, 2.2% experienced febrile neutropenia compared to 19.4%
of TA6/TA7 patients (none of the four TA7/TA7 patients
experienced this side effect). Of the TA7 homozygotes in this
regimen, 66.7% developed grade 3 or 4 diarrhoea compared to
15.2% of TA6/TA6 and 22.6% of TA6/TA7 (P¼0.09). The majority
of severe diarrhoea episodes were not seen in cycle 1 but in
subsequent cycles.
Irinotecan dosing
As described above, we excluded from IRI dose analysis those
patients who received a reduced starting dose of IRI (Figure 1). For
this reason, seven patients randomised to CAPIRI and eight
patients randomised to IRI were excluded. Characteristics of the
patients (n¼203) included in dosage analysis are shown in the
electronic Supplementary Data file.
For CAPIRI, TA7 homozygotes did not receive a lower mean IRI
dose (RDI, P¼0.83) or median number of cycles (P¼0.66; Table 2
and Figure 2). There was no significant difference in the total dose
of IRI received over all cycles: 1.9 gm
 2 (TA7/TA7) compared to
2.1 gm
 2 and 2.0 gm
 2 in TA6/TA6 and TA6/TA7 patients,
respectively (P¼0.51). Likewise, there were no statistically
significant differences in median IRI dosage or number of cycles
between UGT1A1 genotypes treated with IRI (Table 2 and
Figure 2).
Individual dose adjustments in cycle 2 and subsequent cycles
were made to manage serious side effects. The majority of
adjustments occurred in cycles 2 and 3 for both CAPIRI and IRI.
In CAPIRI, 27% of patients with the TA7/TA7 genotype received a
dose reduction, compared to 18% of TA6/TA6 and 21% of TA6/TA7
(P-value for trend: 0.62). Reductions in cycles 2 and 3 were mainly
owing to non-haematological toxicity (n¼13; 87%), which
predominantly consisted of grade X3 diarrhoea. Three patients
experienced febrile neutropenia or infection preceding dose
reduction (one TA6/TA6, one TA6/TA7 and one TA7/TA7). Nine
patients discontinued IRI before tumour evaluation at the third
cycle. The discontinuation was preceded by unacceptable toxicity
in six patients and included grade X3 diarrhoea in all patients, but
none of them experienced neutropenic fever (one TA6/TA6, four
TA6/TA7 and one TA7/TA7).
In the IRI regimen, two of three TA7/TA7 (67%) patients
received a dose reduction during IRI treatment, compared to 17
and 16% of TA6/TA6 and TA6/TA7, respectively. However, this
difference was not statistically significant (P-value for trend: 0.45).
Most of the dose reductions occurred in cycle 2 or 3 and 89%
(n¼8) of these were owing to gastrointestinal toxicity grades X3.
Two patients (22%, TA6/TA6 and TA6/TA7) experienced also
febrile neutropenia or infection preceding dose reduction. Five
patients (all TA6/TA7) discontinued IRI before the first scheduled
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sTable 1 Patient characteristics by regimen
IRI CAPIRI
TA6 TA6 TA7 TA6 TA6 TA7
TA6 TA7 TA7 Total TA6 TA7 TA7 Total
UGT1A1 N¼46 N¼31 N¼3 N¼80 P-value N¼65 N¼62 N¼11 N¼138 P-value
Localisation of primary tumour (%)
Colon 25 (54) 16 (52) 2 (67) 43 (54) P¼0.969
# 33 (51) 36 (58) 7 (64) 76 (55) P¼0.821
#
Rectosigmoid 5 (11) 3 (10) 8 (10) 5 (8%) 3 (5%) 1 (9) 9 (7)
Rectal 16 (35) 12 (39) 1 (33) 29 (36) 27 (42%) 23 (37%) 3 (27) 53 (38)
Gender (%)
Male 25 (54) 23 (74) 3 (100) 51 (64) P¼0.085
# 41 (63%) 41 (66%) 4 (36) 86 (62) P¼0.169
#
Female 21 (46) 8 (26) 29 (36) 24 (37%) 21 (34%) 7 (64) 52 (38)
Age at randomisation
Median (range) 60.5 (46.0–78.0) 61.0 (36.0–78.0) 57.0 (48.0–75.0) 61.0 (36.0–78.0) P¼0.8744
$ 62.0 (44.0–81.0) 63.0 (37.0–78.0) 60.0 (46.0–74.0) 62.0 (37.0–81.0) P¼0.6661
$
Prior adjuvant treatment primary tumour at randomisation (%)
Yes 5 (11) 4 (13) 1 (33) 10 (13) P¼0.520
# 7 (11) 7 (11) 3 (27) 17 (12) P¼0.289
#
No 41 (89) 27 (87) 2 (67) 70 (88)
Predominant localisation of metastases at randomisation (%)
Liver 32 (70) 23 (74) 1 (33) 56 (70) P¼0.495
# 40 (62) 48 (77) 8 (73) 96 (70) P¼0.147
#
Extrahepatic 11 (24) 7 (23) 2 (67) 20 (25) 25 (38) 14 (23) 3 (27) 42 (30)
Unknown 3 (7) 1 (3) 4 (5)
Performance status at start IRI (%)
0 23 (50) 18 (58) 2 (67) 43 (54) P¼0.857
# 39 (60) 38 (61) 5 (45) 82 (59) P¼0.392
#
1 21 (46) 12 (39) 1 (33) 34 (43) 21 (32) 22 (35) 4 (36) 47 (34)
2 1 (2) 1 (1) 4 (6%) 2 (3) 2 (18) 8 (6)
Missing 1 (2) 1 (3) 2 (3) 1 (2%) 1 (o1)
Bilirubin level at start IRI
Median (range) 10.0 (4.0–22.0) 13.0 (7.0–31.0) 27.0 (27.0–27.0) 10.5 (4.0–31.0) P¼0.0009
$ 8.0 (3.0–67.0) 10.0 (1.0–19.0) 13.9 (7.0–24.0) 9.0 (1.0–67.0) P¼0.0106
$
LDH level at start IRI
Median (range) 443.0
(146.0–2316.0)
436.0
(165.0–3493.0)
466.0
(310.0–604.0)
443.0
(146.0–3493.0)
P¼0.9903
$ 410.0
(151.0–2243.0)
360.0
(119.0–3320.0)
336.5
(250.0–1213.0)
377.0
(119.0–3320.0)
P¼0.1778
$
ABCB1 (%)
TT 7 (15) 5 (16) 2 (67) 14 (18) P¼0.215
# 7 (11) 11 (18) 3 (27) 21 (15) P¼0.282
#
TC 19 (41) 14 (45) 1 (33) 34 (43) 36 (55) 34 (55) 3 (27) 73 (53)
CC 20 (43) 12 (39) 32 (40) 22 (34) 16 (26) 5 (45) 43 (31)
Missing 1 (2) 1 (o1)
ABCG2 (%)
TT 36 (78) 18 (58) 3 (100) 57 (71) P¼0.174
# 52 (80) 43 (69) 8 (73) 103 (75) P¼0.458
#
TC 9 (20) 12 (39) 21 (26) 10 (15) 16 (26) 3 (27) 29 (21)
CC 1 (3) 1 (1) 3 (5) 1 (2) 4 (3)
Missing 1 (2) 1 (1) 2 (3) 2 (1)
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stumour evaluation; of these, two patients experienced unaccep-
table toxicity (diarrhoea grade 3).
Bivariate analysis of toxicity
We performed an explorative covariate analysis of patient
characteristics (Table 1) and selected TS, ABCB1 and ABCG2
genotypes as they might confound associations of UGT1A1*28
with febrile neutropenia. We report here only those associations
with P-values o0.05. Genotype distributions (Table 1) are in
accordance with earlier publications (Cascorbi et al, 2001;
Mandola et al, 2003, 2004; Lecomte et al, 2004; de Jong et al,
2004). Binary logistic regression of UGT1A1*28 with febrile
neutropenia suggested that a performance status of 2 or a
rectosigmoid tumour origin both significantly increased the risk
of febrile neutropenia in the first cycle of IRI treatment (odds: 41.7,
P¼0.010 and odds: 6.5, P¼0.030, respectively) in addition to the
association of UGT1A1*28. A performance status of 2 increased
the risk of febrile neutropenia at any time during IRI treatment
13.9-fold (P¼0.022) and in bivariate logistic regression abolished
the level of significance of the UGT1A1*28 association (odds for
TA7/TA7: 18.5, P¼0.128).
DISCUSSION
We investigated three issues concerning UGT1A1*28 genotype and
IRI use: (1) response rates by genotype, (2) association with febrile
neutropenia and (3) dosage adjustments by genotype. We found
that the TA7 allele and the TA7/TA7 genotype are associated with
an increased risk of febrile neutropenia, in patients receiving IRI
and CAPIRI, respectively. Furthermore, tumour response rates
were not significantly different among UGT1A1 genotypes and
TA7/TA7 patients tolerated the same number of IRI cycles and
dosage compared to the other genotypes.
To the best of our knowledge, this is the first study investigating
the effects of UGT1A1*28 genotypes on IRI dose intensity using a
3-week regimen. It is also the first to study the association between
UGT1A1 *28 and febrile neutropenia for IRI monotherapy. In our
opinion, febrile neutropenia is a more relevant clinical end point as
compared to (often uncomplicated) neutropenia, as it results in
hospitalisation and is potentially lethal. The current results
confirm the observed trend of an increased prevalence of severe
haematological toxicity among TA7/TA7 patients (Innocenti
et al, 2004). A similar study by Toffoli et al (2006) shows that
haematological toxicity occurring in the first cycle (but not later
cycles) was related to UGT1A1*28 genotype. However, we found
that TA7/TA7 patients receiving CAPIRI experience a higher risk of
febrile neutropenia at any time during treatment as well as in the
first cycle. Additionally, our results indicate that the performance
status may be a strong predictor of toxicity and patients with a
performance status of 2 may experience an increased risk for
febrile neutropenia during IRI treatment. In bivariate analysis,
performance status was associated with febrile neutropenia
occurring at any cycle, whereas UGT1A1*28 was not. Therefore,
future pharmacogenetic studies associating febrile neutropenia
may consider including performance status as a covariate.
We hypothesised that TA6/TA6 patients might obtain lower
response rates owing to more effective SN-38 glucuronidation. If
so, response rate can possibly be improved by increasing IRI
dosage in these patients. Data on UGT1A1*28 and response to IRI-
based chemotherapy are contradicting. Carlini et al (2005) report a
non-significant trend for an improved response rate in TA7
homozygotes. Ando et al (2000) described that TA7 allele carriers
are at risk of developing severe toxicity by IRI and as a result, they
received lower dosages. The low-dosed patients showed a non-
significant trend towards better response. Higher response rates
for the TA7/TA7 genotype were also found by others (Toffoli et al,
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sTable 2 Response, toxicity and dose during IRI treatment
IRI CAPIRI
TA6 TA6 TA7 TA6 TA6 TA7
UGT1A1 TA6 TA7 TA7 Total TA6 TA7 TA7 Total
Evaluable for response N¼44 N¼30 N¼3 N¼77 P-value N¼61 N¼58 N¼8 N¼127 P-value
Best overall response (%)
CR 1 (2) 3 (5) 1 (13) 5 (4)
PR 7 (16) 4 (13) 11 (14) 29 (48) 22 (38) 4 (50) 55 (43)
SD 27 (61) 16 (53) 3 (100) 46 (60) 27 (44) 30 (52) 2 (25) 59 (46)
PD 10 (23) 10 (33) 20 (26) 4 (7) 3 (5) 1 (13) 8 (6)
Response rate, %,
(95% exact CI)
15.9 (6.6:30.1) 13.3 (3.8:30.7) 0.0 (0%:70.8) 14.3 (7.4:24.1) 0.595
L 49.2 (36.1:62.3) 43.1 (30.2:56.8) 62.5 (24.5:91.5) 47.2 (38.3:56.3) 0.537
L
Disease control, %, rate
(95% exact CI)
77.3 (62.2:88.5) 66.7 (47.2:82.7) 100 (29.2:100) 74.0 (62.8:83.4) 0.240
L 93.4 (84.1:98.2) 94.8 (85.6:98.9) 87.5 (47.3:99.7) 93.7 (88.0:97.2) 0.759
L
TA6 TA6 TA7 TA6 TA6 TA7
UGT1A1 TA6 TA7 TA7 Total TA6 TA7 TA7 Total
Evaluable for toxicity
(grade 3–4)
N¼46 N¼31 N¼3 N¼80 P-value N¼65 N¼62 N¼11 N¼138 P-value
Overall (%)
All cycles 20 (43.5) 12 (38.7) 3 (100) 35 (43.8) Etrend 0.56 33 (50.8) 33 (53.2) 8 (72.7) 74 (53.6) Etrend 0.35
Cycle 1 3 (6.5) 4 (12.9) 0 (0.0) 7 (8.8) FE 0.430 3 (4.6) 6 (9.7) 1 (9.1) 10 (7.2) Etrend 0.44
Febrile neutropenia (%)
All cycles 1 (2.2) 6 (19.4) 0 (0.0) 7 (8.8) FE 0.015 1 (1.5) 4 (6.5) 2 (18.2) 7 (5.1) Etrend 0.031
Cycle 1 1 (2.2) 2 (6.5) 0 (0.0) 3 (3.8) FE 0.561 0 (0.0) 1 (1.6) 2 (18.2) 3 (2.2) Etrend 0.008
Diarrhea
All cycles 7 (15.2) 7 (22.6) 2 (66.7) 16 (20.0) Etrend 0.090 14 (21.5) 14 (22.6) 4 (36.4) 32 (23.2) Etrend 0.43
Cycle 1 3 (6.5) 4 (12.9) 0 (0.0) 7 (8.8) FE 0.430 3 (4.6) 6 (9.7) 1 (9.1) 10 (7.2) Etrend 0.44
TA6 TA6 TA7 TA6 TA6 TA7
UGT1A1 TA6 TA7 TA7 Total TA6 TA7 TA7 Total
Evaluable for dose analysis N¼41 N¼29 N¼3 N¼73 P-value N¼61 N¼58 N¼11 N¼130 P-value
Number of cycles
Median (range) 6 (3–17) 6 (1–15) 8 (4–8) 6 (1–17) 0.33
$ 9 (1–30) 9 (1–32) 9 (1–30) 9 (1–32) 0.66
$
Total dose (g)
Median (range) 4.4 (1.7–11.2) 3.6 (0.7–10.8) 4.0 (2.6–4.9) 4.2 (0.7–11.2) 0.39
$ 3.8 (0.4–10.7) 3.7 (0.4–14.7) 3.0 (0.5–14.7) 3.7 (0.4–14.7) 0.44
$
Total dose (gm
 2)
Median (range) 2.1 (1.0–6.0) 2.0 (0.3–5.3) 2.3 (1.4–2.4) 2.1 (0.3–6.0) 0.25
$ 2.1 (0.3–6.2) 2.0 (0.2–8.0) 1.9 (0.2–7.6) 2.0 (0.2–8.0) 0.51
$
Dose (mgm
 2) per cycle
Median (range) 347 (266–390) 336 (272–364) 302 (284–355) 341 (266–390) 0.45
$ 242 (84–257) 242 (190–277) 242 (156–253) 242 (84–277) 0.83
$
Reduction of IRI after cycle 1 8 5 2 15 0.45
E 12 13 3 28 0.62
E
Cycle of first reduction (%)
Cycle 2–3 4 (50) 4 (80) 1 (50) 9 (60) 0.544
L 5 (42) 9 (69) 1 (33) 15 (54) 0.444
L
Cycle 4–6 1 (13) 1 (20) 2 (13) NS 4 (33) 2 (15) 1 (33) 7 (25) NS
Cycle 7–9 1 (13) 1 (50) 2 (13) NS 2 (17) 1 (8) 1 (33) 4 (14) NS
Cycle X10 2 (25) 2 (13) NS 1 (8) 1 (8) 2 (7) NS
CAPIRI¼irinotecan first-line combination therapy (250mgm
 2 every 3 weeks, with capecitabine); CI¼confidence interval; CR¼complete response; E¼exact; Etrend¼exact-values for trend; FE¼Fisher’s exact; IRI¼irinotecan
(350mgm
 2 every 3 weeks) second-line single-agent therapy; L¼logistic regression; NS¼statistically non-significant difference; PD¼progressive disease; PR¼partial response; SD¼stable disease.
Response is defined as CR or PR, disease control as CR, PR or SD.
P-values are calculated by L, Etrend, E, FE or Kruskal–Wallis.
$Kruskal–Wallis.
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s2006). In contrast, Marcuello et al (2004) reported that patients
with the UGT1A1*28 polymorphism receiving IRI did not have a
higher response rate but experienced shorter overall survival. In
our study, similar to others (Liu et al, 2008), we found that TA6/
TA6 patients had no significantly different antitumour efficacy
compared to patients with other UGT1A1 genotypes.
One would expect that TA7/TA7 patients received fewer numbers
of cycles and lower RDI owing to more febrile neutropenia. Indeed,
a recent study with 2-week IRI (Liu et al, 2008) found that the need
for dose reduction was associated with the TA7/TA7 genotype, but
this association was not found by others (Toffoli et al, 2006).
However, in 3-week CAPIRI, diarrhoea, and not neutropenia, may
be the primary dose-limiting toxicity (Carlini et al, 2005; Koopman
et al, 2006). Indeed, nearly all dose reductions in cycles 2–3 in our
study were preceded only by gastrointestinal toxicity. Likewise,
most patients who discontinued IRI use within the first three
cycles experienced severe (grade X3) diarrhoea but not neutro-
penic fever. However, severe diarrhoea may occur more frequently
in 3-week regimens with higher IRI dosages. In these regimens, the
influence of febrile neutropenia (and the UGT1A1*28 polymor-
phism) on dose intensity may be less pronounced compared to the
2-week regimen.
In conclusion, we observed that the UGT1A1*28 genotype
is associated with an enhanced risk of febrile neutropenia but
not with IRI dose reductions. However, upfront dose reduction
may result in a lower incidence of febrile neutropenia in these
patients.
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